Equities Analysts Set Expectations for Zeltiq Aesthetics Inc.’s Q4 2016 Earnings (ZLTQ)
Zeltiq Aesthetics Inc. (NASDAQ:ZLTQ) – Equities research analysts at William Blair upped their Q4 2016 earnings per share estimates for Zeltiq Aesthetics in a report released on Thursday. William Blair analyst M. Kaczor now anticipates that the brokerage will post earnings per share of $0.22 for the quarter, up from their prior estimate of $0.19. William Blair also issued estimates for Zeltiq Aesthetics’ Q4 2017 earnings at $0.18 EPS and FY2017 earnings at $0.08 EPS.
Zeltiq Aesthetics (NASDAQ:ZLTQ) last announced its quarterly earnings results on Wednesday, November 9th. The company reported $0.12 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.08 by $0.04. Zeltiq Aesthetics had a negative return on equity of 6.45% and a net margin of 9.48%. The business earned $95.20 million during the quarter, compared to the consensus estimate of $90.84 million. During the same quarter last year, the firm posted $0.05 EPS. The company’s quarterly revenue was up 55.6% on a year-over-year basis.
ZLTQ has been the subject of several other research reports. Zacks Investment Research upgraded Zeltiq Aesthetics from a “hold” rating to a “buy” rating and set a $41.00 price objective for the company in a report on Wednesday, October 26th. Leerink Swann restated an “outperform” rating and set a $48.00 price objective on shares of Zeltiq Aesthetics in a report on Thursday, August 25th. Brean Capital restated a “buy” rating on shares of Zeltiq Aesthetics in a report on Monday, October 24th. Stifel Nicolaus boosted their price objective on Zeltiq Aesthetics from $38.00 to $52.00 and gave the company a “buy” rating in a report on Wednesday, September 21st. Finally, JPMorgan Chase & Co. restated a “hold” rating and set a $35.00 price objective (up previously from $27.00) on shares of Zeltiq Aesthetics in a report on Tuesday, August 9th. Two investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $42.78.
Shares of Zeltiq Aesthetics (NASDAQ:ZLTQ) opened at 39.41 on Friday. Zeltiq Aesthetics has a one year low of $18.41 and a one year high of $41.48. The firm’s 50-day moving average price is $37.67 and its 200 day moving average price is $33.39. The firm has a market cap of $1.57 billion, a P/E ratio of 50.85 and a beta of 0.89.
Several hedge funds and other institutional investors have recently modified their holdings of ZLTQ. Samlyn Capital LLC purchased a new position in shares of Zeltiq Aesthetics during the first quarter worth approximately $29,100,000. BlackRock Fund Advisors boosted its position in shares of Zeltiq Aesthetics by 134.5% in the first quarter. BlackRock Fund Advisors now owns 2,098,036 shares of the company’s stock worth $56,983,000 after buying an additional 1,203,254 shares in the last quarter. Riverbridge Partners LLC boosted its position in shares of Zeltiq Aesthetics by 14.2% in the second quarter. Riverbridge Partners LLC now owns 1,166,362 shares of the company’s stock worth $31,877,000 after buying an additional 144,781 shares in the last quarter. RS Investment Management Co. LLC boosted its position in shares of Zeltiq Aesthetics by 35.3% in the second quarter. RS Investment Management Co. LLC now owns 1,056,821 shares of the company’s stock worth $28,883,000 after buying an additional 275,499 shares in the last quarter. Finally, Deerfield Management Co. purchased a new position in shares of Zeltiq Aesthetics during the first quarter worth approximately $29,996,000.
In other news, Director Kevin C. Oboyle sold 7,500 shares of the company’s stock in a transaction on Thursday, September 15th. The stock was sold at an average price of $40.08, for a total transaction of $300,600.00. Following the transaction, the director now owns 19,485 shares of the company’s stock, valued at approximately $780,958.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Keith J. Sullivan sold 8,000 shares of the company’s stock in a transaction on Friday, November 4th. The shares were sold at an average price of $33.01, for a total value of $264,080.00. Following the transaction, the insider now directly owns 82,023 shares in the company, valued at approximately $2,707,579.23. The disclosure for this sale can be found here. 15.60% of the stock is owned by company insiders.
Zeltiq Aesthetics Company Profile
ZELTIQ Aesthetics, Inc is a medical technology company. The Company focuses on developing and commercializing products utilizing its controlled-cooling technology platform. Its product, the CoolSculpting System, is designed to reduce stubborn fat bulges. It sell the CoolSculpting system primarily to dermatologists, plastic surgeons, aesthetic specialists, and obstetrics and gynecology physicians.
Receive News & Stock Ratings for Zeltiq Aesthetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zeltiq Aesthetics Inc. and related stocks with our FREE daily email newsletter.